TLR5 agonist in combination with anti-PD-1 treatment enhances anti-tumor effect through M1/M2 macrophage polarization shift and CD8<sup>+</sup> T cell priming.

导出 OA

翻译打印收藏纠错

第一作者： Junseok,Lee

第一单位： Institute for Translational Research and Molecular Imaging, The Catholic University of Korea, Seoul, Republic of Korea.

作者： Junseok,Lee ^[1] ; Keon-Il,Im ^[2] ; Sojin,Gil ^[1] ; Hyemin,Na ^[1] ; Gi-June,Min ^[2] ; Nayoun,Kim ^[1] ; Seok-Goo,Cho ^[2]

作者单位： Institute for Translational Research and Molecular Imaging, The Catholic University of Korea, Seoul, Republic of Korea. ^[1] Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. ^[2] Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. ^[3] Institute for Translational Research and Molecular Imaging, The Catholic University of Korea, Seoul, Republic of Korea. chosg@catholic.ac.kr. ^[4] Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. chosg@catholic.ac.kr. ^[5] Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. chosg@catholic.ac.kr. ^[6]

关键词 Cancer immunotherapy Immune checkpoint PD-1 TLR5 Tumor-associated macrophages